Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 15/20 | 0.60 |
| ▸ | KCNJ1 | P48048 | 14/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2726359 | 0.81 | KCNH2 (0.61) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL2728949 | 0.80 | KCNH2 (0.58) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL2730838 | 0.80 | KCNJ1 (0.60) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL2723126 | 0.80 | KCNH2 (0.60) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL2731395 | 0.76 | KCNJ1 (0.56) | KCNH2KCNJ1SIGMAR1 | |
| SCHEMBL10234055 | 0.76 | KCNJ1 (1.00) | KCNH2KCNJ1 | |
| SCHEMBL2722823 | 0.74 | KCNH2 (0.47) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL9321244 | 0.73 | KCNH2 (0.55) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL2731394 | 0.72 | KCNJ1 (0.52) | KCNH2KCNJ1HRH3 | |
| SCHEMBL4840441 | 0.69 | SIGMAR1 (0.50) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632465-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9073882-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2632465-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| WO-2012058116-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNH2 16/4885KCNJ1 2/4885SIGMAR1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.